XPR1 and inflammatory bowel disease: The agonist INT-747, a Farnesoid X receptor agonist, significantly reduces TNF-α secretion in activated human peripheral blood monocytes, purified CD14 monocytes and DCs, and monocytes from the lamina propria of inflammatory bowel disease (IBD) patients (113).